# A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis

> **NCT06943950** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Ouyi Pharmaceutical Co., Ltd.** · enrollment: 500 (estimated)

## Conditions studied

- Moderate to Severe Plaque Psoriasis

## Interventions

- **DRUG:** SYHX1901

## Key facts

- **NCT ID:** NCT06943950
- **Lead sponsor:** CSPC Ouyi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-04-28
- **Final completion:** 2027-06-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06943950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06943950, "A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06943950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*